Tevogen Bio Estimates TVGN 116 Cumulative 5-Yr Top-Line Revenue To Be ~$6.5B; Risk Adjusted Net Present Value For TVGN 116 Is Estimated To Exceed ~$325M In US Alone

Author: Benzinga Newsdesk | September 09, 2025 03:20pm
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ: TVGN), today shared asset value and potential forecast for the Company's pipeline product, TVGN 116, for liver cancer prevention with high-risk chronic Hepatitis

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today shared asset value and potential forecast for the Company's pipeline product, TVGN 116, for liver cancer prevention with high-risk chronic Hepatitis B infections.

The TVGN 116 cumulative 5-year top-line revenue forecast is estimated to be ~$6.5 billion. The forecast reflects the Company's unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

The current rNPV projection for this internally developed asset exceeds ~$325 million. This is based on our current understanding of the unmet medical needs and the competitive landscape. The risk adjustment resets at each milestone in the product development lifecycle, and Tevogen's progress with its first clinical-stage product, TVGN 489, highlights the rapid pace at which such milestones can be achieved.

Posted In: TVGN